Research programme: membrane protein inhibitors - PfizerAlternative Names: Efflux pump inhibitors research programme - Pfizer
Latest Information Update: 05 Aug 2009
At a glance
- Originator Pfizer
- Mechanism of Action Membrane protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 05 Aug 2009 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 02 Feb 2006 Preclinical trials in Bacterial infections in USA (unspecified route)